Read the fact sheet to learn more.

The post Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage first appeared on Resyca.

Journal: International Journal of Pharmaceutics, Volume 683, 2025

Abstract: The COVID-19 pandemic has emphasised the need for innovative and efficient drug delivery systems, particularly for nucleic acid-based therapeutics.

Lipid nanoparticle (LNP)-based small interfering RNA (siRNA) technology provides a promising strategy for gene therapy, immune modulation, and targeted molecular medicine. Intranasal delivery of LNP-siRNA formulations offers advantages such as efficient gene silencing and non-invasive administration.

However, the nasal spray device plays a crucial role in determining the deposition patterns within the nasal cavity and can impact the physicochemical stability of LNP formulations during aerosolisation. In this study, the Rayleigh Jet Nasal Atomiser was evaluated for its performance in delivering three LNP-siRNA formulations designed based on the LNP structures of Moderna, Pfizer, and Alnylam (Onpattro) marketed formulations, respectively.

Key nanoparticle characteristics, including particle size distribution, polydispersity index (PDI), zeta potential, and encapsulation efficiency, as well as aerosol properties such as droplet size, were analyzed before and after aerosolisation. Deposition patterns were assessed using the Alberta Idealized Nasal Inlet (AINI) model to determine the distribution of aerosolized LNPs. The results demonstrate that the Rayleigh Jet Nasal Atomizer efficiently delivers all the three formulations to the nasal cavity, primarily targeting the nasopharynx, while minimizing deposition in the lower respiratory tract.

Additionally, the device maintained LNPs structural integrity, although a reduction in encapsulated siRNA concentration suggests partial LNP disruption during aerosolisation. These findings indicate that the Rayleigh Jet Nasal Atomiser is a suitable device for intranasal delivery of LNP-based siRNA therapeutics, offering a promising approach for nasal administration of RNA-based drug delivery.

Reference

The post Evaluation of Rayleigh jet atomiser for intranasal delivery of lipid nanoparticle – siRNA formulations: stability, deposition, and device performance first appeared on Resyca.

Journal: International Journal of Pharmaceutics, Volume 672, 2025

Abstract: The nasal delivery of mRNA vaccines attracts great interests in both academia and industry. While the lipid nanoparticle (LNP)-mRNA complexes are vulnerable and need a subtle process for aerosolisation. In this study, a new nasal atomiser, based on the working rationale of Rayleigh breakup, was employed to aerosolise LNP-mRNAs.

The data revealed no statistical differences in physiochemical properties before and after aerosolisation, strongly suggesting LNP-mRNAs be well preserved upon aerosolisation by Rayleigh breakup technology.

Additionally, these Rayleigh breakup droplets showed a physical size of ∼25 µm in mean with a narrow size distribution (Span: 1.24) and demonstrated a large portion (70–80 % w/w) greater than 10 µm in aerodynamic diameter, strongly suggesting a predominate deposition in the upper airway and designating a great appropriateness for nasal drug delivery.

Furthermore, the recently developed Alberta Idealized Nasal Inlet (AINI) was utilized to evaluate the regional nasal deposition of LNP-mRNA aerosols.

It was demonstrated that, at the administration angle of 45°, the major deposition of mRNAs (>50 % w/w) was in the target region of turbinates.

The inhalation airflow at 7.5 L/min can maximize the targeted delivery of mRNA (∼64 % w/w) and minimise the undesirable depositions in other segments.

This study provides a new approach to aerosolise LNP-mRNAs with undisturbed stabilities for targeted nasal vaccine delivery.

Reference

The post Targeted nasal delivery of LNP-mRNAs aerosolised by Rayleigh breakup technology first appeared on Resyca.

Event: DDL 2024, 11 – 13 December 2024, Edinburgh, United Kingdom

Abstract: The nasal administration route has garnered substantial interest for vaccination and nose-to-brain delivery via the olfactory region.

Current swirl nozzle devices deliver less than 5-10% of their dose to the target region. A novel pre-filled syringe soft mist nasal spray delivers over 40% to the olfactory region, significantly improving delivery efficiency for nose to brain applications, with the ability to target regions of interest for nasal vaccines, such as the posterior nasal cavity.

The post Pre-filled syringe soft mist nasal spray for improved intranasal drug delivery first appeared on Resyca.

Publication: Drug Development & Delivery, Volume 24(7), 2024

Abstract: Worldwide, rising cases of chronic lung conditions, such as asthma, cystic fibrosis, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD), are driving demand for inhalation drug delivery devices.

As respiratory diseases rise and biologics rapidly expand, the need for advanced, patient-friendly delivery solutions is accelerating. This article explores how Soft Mist Inhaler (SMI) technology is opening new pathways for inhaled and nasal biologics – from improving dosing performance to reducing reliance on needle-based administration.

By reading our article, you’ll discover:

• Why inhalation and nasal delivery are becoming strategic routes for biologics.
• How reformulation into inhaled or nasal formats can extend product life cycles.
• The key challenges of delivering sensitive biologics — and how soft mist technology overcomes them.
• The critical role of industry partnerships in accelerating device innovation and development efficiency.

Download the full article to find out more.

The post How soft mist inhalers support improved biopharma drug delivery first appeared on Resyca.

Publication: International Pharmaceutical Industry, Volume 16(1), 2024

Abstract: Biologics are reshaping modern healthcare, yet their full potential is often constrained by traditional administration routes. Recent advances in nasal inhalation, particularly soft mist nasal spray technologies, are redefining what is possible for sensitive biopharmaceutical formulations.

The rapid growth of both inhalation technologies and the global biologics market is creating new opportunities for patient-friendly, non-invasive drug delivery. Nasal inhalation and especially soft mist nasal spray technology, is emerging as a strong alternative to traditional parenteral routes, offering fast systemic uptake, improved patient experience, and expanded access beyond clinical settings.

However, biologics bring unique development challenges, including formulation sensitivity and the need for precise, consistent nasal deposition. Resyca’s next-generation soft mist nasal spray platforms address these barriers through biologic-compatible nozzle designs, controlled plume characteristics, and device architectures that minimise formulation stress while enhancing delivery efficiency.

As patent expiries accelerate competition in the biologics sector, nasal reformulation becomes a strategic path to lifecycle extension. Soft mist nasal sprays enable developers to differentiate existing products, streamline regulatory pathways, and unlock new therapeutic potential, positioning nasal delivery as a pivotal innovation for the next era of biopharmaceuticals.

Download

The post Transforming the biologics product lifecycle with inhalation innovation first appeared on Resyca.

Journal: Pharmaceutics, Volume 16(2), 2024

Abstract: Currently, nasal administration of active pharmaceutical ingredients is most commonly performed using swirl-nozzle-based pump devices or pressurised syringes.

However, they lead to limited deposition in the more active regions of the nasal cavity, especially the olfactory region, which is crucial for nose-to-brain drug delivery. This research proposes to improve deposition in the olfactory region by replacing the swirl nozzle with a nanoengineered nozzle chip containing micrometer-sized holes, which generates smaller droplets of 10–50 μm travelling at a lower plume velocity.

Two nanotech nozzle chips with different hole sizes were tested at different inhalation flow rates to examine the deposition patterns of theophylline, a hyposmia treatment formulation, using a nasal cavity model. A user study was also conducted and showed that the patient instructions influenced the inhalation flow rate characteristics. Targeted flow rates of between 0 and 25 L/min were used for the in vitro deposition study, yielding 21.5–31.5% olfactory coverage. In contrast, the traditional swirl nozzle provided only 10.8% coverage at a similar flow rate. This work highlights the potential of the nanotech soft mist nozzle for improved intranasal drug delivery, particularly to the olfactory region.

Reference

The post Improved olfactory deposition of theophylline using a nanotech soft mist nozzle chip first appeared on Resyca.

Event: DDL 2023, 6 – 8 December 2023, Edinburgh, United Kingdom

Abstract: Soft mist inhalers (SMIs) are propellant-free inhalers that are gaining interest in the delivery of drugs, especially proteins and biologics, due to the low shear stress they produce during aerosolisation and low carbon footprint. The effectiveness of the SMI inhalation therapy relies on many factors, including the device manufacture and physicochemical properties of the inhalation solution.

The Aim of the study was to evaluate the influence of fluid physiochemical properties on droplet size distribution using the Pulmospray™ SMI device, (Resyca B.V, Enschede, Netherlands).

Specifically, we will evaluate the following properties: fluid viscosities, ionic strength and surface tension of different fluid mixtures and study their particle size distribution at two different inhalation flow rates.

In conclusion, the single-use Pulmospray™ SMI device is an efficient inhaler for the delivery of drug products to the lungs with varying physiochemical properties of the inhalation solution and inspiratory flow rates.

The post Influence of fluid physiochemical properties on aerosolisation performance of a novel soft mist inhaler first appeared on Resyca.

Journal: Nature Scientific Report, Volume 13(1), 2023

Abstract: Nebulisation of mRNA therapeutics can be used to directly target the respiratory tract.

A promising prospect is that mucosal administration of lipid nanoparticle (LNP)-based mRNA vaccines may lead to a more efficient protection against respiratory viruses.

However, the nebulisation process can rupture the LNP vehicles and degrade the mRNA molecules inside. Here we present a novel nebulisation method able to preserve substantially the integrity of vaccines, as tested with two SARS-CoV-2 mRNA vaccines.

We compare the new method with well-known nebulisation methods used for medical respiratory applications. We find that a lower energy level in generating LNP droplets using the new nebulisation method helps safeguard the integrity of the LNP and vaccine.

By comparing nebulisation techniques with different energy dissipation levels we find that LNPs and mRNAs can be kept largely intact if the energy dissipation remains below a threshold value, for LNP integrity 5–10 J/g and for mRNA integrity 10–20 J/g for both vaccines.

Reference

The post Low energy nebulisation preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery first appeared on Resyca.

Publication: International Pharmaceutical Industry, Volume 14(2), 2022

Abstract: The COVID-19 outbreak has provided a number of lessons for the pharmaceutical industry to consider for future pandemics. Could soft mist inhalers (SMIs), and soft mist nasal sprays in particular, hold the key to improved vaccine delivery?

Biologic vaccines are highly sensitive, and conventional nasal devices can compromise formulation integrity or fail to deliver consistent doses. Next-generation soft mist inhalers (SMIs) and soft mist nasal sprays address these challenges through controlled plume dynamics, narrow spray cone angles, and biologic-compatible nozzle designs that enhance deposition in the upper nasal cavity while minimising particle damage.

Built on modular, standardised platforms, these devices also streamline development, reduce customisation needs, and support faster regulatory and commercialisation timelines. As a result, SMIs and soft mist nasal sprays offer a practical, scalable route to unlocking the full potential of nasal vaccines—strengthening global preparedness and enabling more efficient, accessible vaccination strategies for future pandemics.

Find out more in our article.

The post SMIs & Soft Mist Nasal Sprays – A key defence in the fight against the next pandemic? first appeared on Resyca.